Branched-chain amino acids for the treatment of neuronal injury

An amino acid and composition technology, applied in the field of branched chain amino acid entities, can solve problems such as limited curative effect period

Pending Publication Date: 2020-06-16
AXCELLA HEALTH INC
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current therapies for stroke include intravenous thrombolytic agents, which have a limited duration of efficacy after the onset of the stroke and have side effects (eg, risk of intracerebral hemorrhage) and contraindications (eg, use of anticoagulants or uncontrolled high blood pressure). blood pressure)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Branched-chain amino acids for the treatment of neuronal injury
  • Branched-chain amino acids for the treatment of neuronal injury
  • Branched-chain amino acids for the treatment of neuronal injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0263] Example 1. Cytokinin levels in microglia treated with amino acid compositions.

[0264] Neuroinflammation and microglial activation are key mediators of repair and recovery after traumatic brain injury (TBI). However, recent clinical and laboratory data have demonstrated that TBI can cause persistent neuroinflammation and microglial activation, in some cases for many years, and can lead to chronic neurodegeneration, dementia, and encephalopathy. Prospective studies of TBI biomarkers in adults with severe TBI have demonstrated chronically increased serum levels of IL-1β, IL-6, CXCL8, IL-10, and tumor necrosis factor (TNFα).

[0265] Pups were decapitated, brains were removed from the skulls, cortices were excised and collected in calcium- and magnesium-free Hanks' balanced salt solution (CMF-HBSS) on ice. Mince cortex with a sterile razor blade in mincing solution (CMF-HBSS) and 2 ml of digestion solution (0.25% trypsin in CMF-HBSS) in a 15 ml sterile plastic tube in a ...

Embodiment 2

[0278] Example 2. Efficacy assessment of amino acid compositions in a rat model of TBI.

[0279] Adult male Sprague-Dawley rats (250-350 g) from Charles River were used. Animals were housed 2 per cage in polycarbonate rat cages equipped with microisolators and acclimated for up to 7 days. All rats were inspected, handled and weighed to assess adequate health and fitness before starting the study. A 12 / 12 light / dark cycle was maintained during the study. The room temperature was maintained between 20°C and 23°C and the relative humidity was maintained at about 50%. Feed and water were provided ad libitum for the duration of the study. The animals are randomly assigned to treatment groups.

[0280] Among several animal models of TBI, the controlled cortical impingement (CCI) model is the most commonly used and the only one commercially available. Compared with other models, the CCI model can control all mechanical factors such as the time, speed and depth of impact, and in ...

Embodiment 3

[0295] Example 3. Treatment of Individuals Suffering from TBI with Amino Acid Compositions.

[0296] A feature of the studies described herein was the administration of compositions comprising amino acids to patients suffering from TBI. Adult individuals 18 to 35 years old (inclusive) suffering from mild traumatic brain injury resulting from any sports-related event or blunt trauma to the head will be administered the amino acid composition. The composition contained L-leucine, L-isoleucine, L-valine, N-acetylcysteine ​​(NAC) and acetyl-L-carnitine (ALCAR) (Table 8). The individual will receive approximately 17.1 g of the amino acid composition twice daily for a total of 34.2 g per day.

[0297] Table 8. Exemplary components and amounts of amino acid compositions for treating individuals suffering from TBI.

[0298]

[0299] This study was primarily used to evaluate the safety, tolerability and pharmacokinetics of the composition administered for 8 days in adult individua...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
depthaaaaaaaaaa
Login to view more

Abstract

Disclosed are compositions comprising branched chain amino acids, N-acetylcysteine and acetyl-L-carnitine for use in treating or preventing neuronal injury in a subject, e.g., a subject at risk of orhaving traumatic brain injury or stroke.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Application Serial No. 62 / 545,364, filed August 14, 2017, U.S. Application Serial No. 62 / 614,198, filed January 5, 2018, and U.S. Application Serial No. 62 / 697,690; the above-mentioned patent application is hereby incorporated by reference in its entirety. Background technique [0003] Traumatic brain injury (TBI) is the leading cause of death and disability in children and young adults in the United States. An estimated 3 million Americans suffer from TBI each year. Traumatic brain injury (TBI) is characterized by impairment of normal brain function due to an acute external force. Although TBI can be mild and cause no long-term disability, TBI is also a major cause of disability and even death worldwide. Regardless of the incidence of TBI, current treatments focus on stabilizing the patient without preventing further injury and without addressing the neuronal damage caused by the trauma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61K31/221A61K38/00A61K45/06A61K9/00A23L2/00A61P9/10A61P25/00A61P25/28A61P43/00
CPCA61K45/06A61K9/0095A61K31/221A61K38/063A23L2/52A61K31/198A61K38/05A61K38/06A61P25/28A23L33/175A23L33/18A23V2002/00A61K2300/00A23V2200/322A23V2250/0626A23V2250/0628A23V2250/0634A23V2250/0654A61K31/197A61K31/18A23V2250/306
Inventor 吉安路卡·德 瑞恩佐瑞弗·亚非恩肖恩·卡罗尔马修·拉塞尔
Owner AXCELLA HEALTH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap